Skip to Content


In the US, Erlotinib (erlotinib systemic) is a member of the drug class EGFR inhibitors and is used to treat Non-Small Cell Lung Cancer, Pancreatic Cancer and Renal Cell Carcinoma.

US matches:

UK matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Category

Cytostatic agent: Epidermal growth factor receptor tyrosine kinase inhibitor

Chemical Names

4-Quinazolinamine, N-(3-etynylphenyl)-6,7-bis(2-metoxyetoxy)-,

N-(3-etynylphenyl)-6,7-bis(2-metoxyetoxy)chinazolin-4-amin (IUPAC)

N-(3-etynylphenyl)-6,7-bis(2-metoxyetoxy)quinazolin-4-amine (WHO)

Foreign Names

  • Erlotinibum (Latin)
  • Erlotinib (German)
  • Erlotinib (French)
  • Erlotinib (Spanish)

Generic Names

  • Erlotinib (OS: BAN)
  • Erlotinib Hydrochloride (OS: USAN, BANM, JAN)
  • CP-358,774-01 (IS)
  • NSC 718781 (IS)
  • OSI-774 (IS: Osi)
  • R-1415 (IS)

Brand Names

  • Erleva
    Glenmark, India
  • Tarcenib
    Techno, Bangladesh
  • Tarceva
    Roche, Colombia; Roche, Georgia; Roche, Hong Kong; Roche, Israel; Roche, Lebanon; Roche, Philippines; Roche, Turkey; Roche, Vietnam; Chugai Pharmaceutical, Japan; F. Hoffmann-La Roche LTD, Serbia; Genentech, United States; Haemato Pharm, Austria; Hoffmann-La Roche, Bosnia & Herzegowina; Productos Roche, Chile; Roche, Armenia; Roche, Argentina; Roche, Australia; Roche, Belgium; Roche, Canada; Roche, China; Roche, Czech Republic; Roche, Germany; Roche, Denmark; Roche, Ecuador; Roche, Egypt; Roche, Spain; Roche, Finland; Roche, France; Roche, Greece; Roche, Croatia (Hrvatska); Roche, Hungary; Roche, Indonesia; Roche, Ireland; Roche, Iceland; Roche, Italy; Roche, Moldova; Roche, Myanmar; Roche, Mexico; Roche, Netherlands; Roche, Norway; Roche, New Zealand; Roche, Oman; Roche, Poland; Roche, Portugal; Roche, Romania; Roche, Sweden; Roche, Thailand; Roche, Taiwan; Roche, Uruguay; Roche, South Africa; Roche Products, United Kingdom; Roche Registration, Austria; Roche, Lithuania


BANBritish Approved Name
BANMBritish Approved Name (Modified)
IUPACInternational Union of Pure and Applied Chemistry
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.